Table 3.

Change from Baseline to Week 12 for biochemical, clinical, and cognitive measures, not adjusted for genotypes

Measure	df	L-Methylfolate	Placebo	Difference
BLOOD CHEMISTRIES
Plasma methylfolate, nmol/L	51	582 (400 to 765), p<.0001	−1 (−183 to 181), p=.99	583 (326 to 841), p<.0001
Plasma homocysteine, μmol/L	51	−2.8 (−5.5 to −0.2), p=.03	0.6 (−2.0 to 3.2), p=.64	−3.5 (−7.2 to 0.2), p=.07
Plasma methionine, μmol/L	51	−3.4 (−10.7 to 4.0), p=.36	−4.0 (−10.0 to 2.0), p=.16	0.6 (−8.6 to 9.9), p=.89
Plasma B12, pmol/L	51	−26 (−86 to 34), p=.38	8 (−53 to 69), p=.79	−34 (−120 to 52), p=.43
SYMPTOMS/COGNITION
PANSS total	52	−4.7 (−8.2 to −1.3), p=.008	−1.5 (−5.0 to 1.9), p=.38	−3.2 (−8.1 to 1.7), p=.19
PANSS positive	52	−1.2 (−2.4 to 0.1), p=.07	−1.5 (−2.8 to −0.2), p=.02	0.3 (−1.5 to 2.1), p=.71
PANSS negative	52	−1.3 (−2.6 to 0.0), p=.05	0.9 (−0.4 to 2.2), p=.19	−2.1 (−4.0 to −0.3), p=.02
PANSS general	52	−2.5 (−4.7 to −0.4), p=.02	−0.6 (−2.8 to 1.6), p=.60	−2.0 (−5.1 to 1.1), p=.21
SANS total	52	−0.5 (−3.5 to 2.5), p=.73	2.4 (−0.6 to 5.4), p=.11	−2.9 (−7.1 to 1.3), p=.17
CDSS total	52	−0.0 (−1.0 to 0.9), p=.95	−0.7 (−1.7 to 0.2), p=.12	0.7 (−0.6 to 2.0), p=.29
MATRICS composite total	48	1.1 (−1.0 to 3.1), p=.31	−0.4 (−2.6 to 1.8), p=.70	1.5 (−1.5 to 4.5), p=.33

Values given as mean (95% confidence interval). df=degrees of freedom, PANSS=Positive and Negative Syndrome Scale, SANS=Scale for Assessment of Negative Symptoms, CDSS=Calgary Depression Scale for Schizophrenia, MATRICS=Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.